Preoperative reverse transcriptase polymerase chain reaction for prostate specific antigen predicts treatment failure following radical prostatectomy

Journal of Urology

Volumn 155, Issue 5, 1996, Pages 1557-1562

  Olsson, Carl A ^a   De Vries, Glen M ^a   Raffo, Anthony J ^a   Benson, Mitchell C ^a   O'Toole, Kathleen ^a   Cao, Yichen ^a   Buttyan, Ralph E ^a   Katz, Aaron E ^a  

^a The New York Presbyterian Hospital   (United States)

Author keywords

antigens; polymerase chain reaction; prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CANCER RECURRENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RECURRENT DISEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT;

EID: 0029918964     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)66125-1     Document Type: Article

References (37)

1. Brendler, C. B. and Walsh, P. C.: The role of radical prostatectomy in the treatment of prostate cancer. CA, 42: 212, 1992.
2. McNeal, J. E., Bostwick, D. G., Kindrachuk, R. A., Redwine, E. A., Freiha, F. S. and Stamey, T. A.: Patterns of progression in prostate cancer. Lancet, 1: 60, 1986.
3. Catalona, W. J. and Smith, D. S.: 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J. Urol, part 2, 152: 1837, 1994.
4. Partin, A. W., Pound, C. R., Clemens, J. Q., Epstein, J. I. and Walsh P. C.: Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol. Clin. N. Amer., 20: 713, 1993.
5. Larner, J., Gay S., Grizos, W., Fortier, G. and Malcom, R.: Significance of CT-scan-detected seminal vesicle enlargement in prostate cancer. A pilot study. Urology, 41: 259, 1993.
6. Outwater, E. K., Petersen, R. O., Siegehnan, E. S., Gomella, L. G., Chernesky, C. E. and Mitchell, D. G.: Prostate carcinoma: assessment of diagnostic criteria for capsular penetration on endorectal coil MR images. Radiology, 193: 333, 1994.
7. Ravery, V., Boccon-Gibod, L. A., Meulemans, A., Dauge-Geffroy, M. C., Toublanc, M. and Boccon-Gibod, L.: Predictive value of pathological features for progression after radical prostatectomy. Eur. Urol., 26: 197, 1994.
8. Katz, A. E., Olisson, C. A., Raffo, A., Cama, C., Perlman, H., Seaman, E., O'Toole, K. M., McMahon, D., Benson, M. C. and Buttyan, R.: Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay. Urology, 43: 765, 1994.
9. Katz, A. E., de Vries, G. M., Begg, M. D., Raffo, A. J., Cama, C., O'Toole, K., Buttyan, R. E., Benson, M. C. and Olsson, C. A.: Enhanced reverse transcriptase-polymerase chain reaction for prostate specific antigen as an indicator of true pathologic stage in patients with prostate cancer. Cancer, 75: 1642, 1995.
10. Whitmore, W. F., Jr., Catalona, W. J., Grayhack, J. T., Hanks, G., Peters, P. C., Shipley, W. U. and Walsh, P. C.: Organ systems program staging classification for prostate cancer. In: A Multidisciplinary Analysis of Controversies in the Management of Prostate Cancer. Edited by D. S. Coffey, M. I. Resnick, F. A. Dorr and J. P. Karr. New York: Plenum Press, pp. 295-298, 1988.
11. Kaplan, E. L. and Meier P.: Nonparametric estimation from incomplete observations. J. Amer. Stat. Ass., 53: 457, 1958.
12. Cama, C., Olsson, C. A., Raffo, A. J., Perlman, H. Buttyan, R., O'Toole, K., McMahon, D., Benson, M. C. and Katz, A. E.: Molecular staging of prostate cancer. II. A comparison of the application of an enhanced reverse transcriptase polymerase chain reaction assay for prostate specific antigen versus prostate specific membrane antigen. J. Urol., 153: 1373, 1995.
13. Wood, D. P., Jr., Banks, E. R., Humphreys, S., McRoberts, J. W. and Rangnekar, V. M.: Identification of bone marrow micrometastases in patients with prostate cancer. Cancer, 74: 2533, 1994.
14. Jaakkola, S., Vornanen, T., Leinonen, J., Rannikko, S. and Stenman, U. H.: Detection of prostatic cells in peripheral blood: correlation with serum concentrations of prostate-specific antigen. Clin. Chem., 41: 182, 1995.
15. Ghossein, R. A., Scher, H. I., Gerald, W. L., Kelly, W. K., Curley, T., Amsterdam, A., Zhang, Z. F. and Rosai, J.: Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implications. J. Clin. Oncol., 13: 1195, 1995.
16. Seiden, M. V., Kantoff, P. W., Krithivas, K., Propert, K., Bryant, M., Haltom, E., Gaynes, L., Kaplan, I., Bubley, G. and DeWolf, W.: Detection of circulating tumor cells in men with localized prostate cancer. J. Clin. Oncol., 12: 2634, 1994.
17. Lu-Yao, G., McLerran, D., Wasson, J. and Wennberg, J.: An assessment of radical prostatectomy. Time trends, geographic variation, and outcomes. The Prostate Patient Outcomes Research Team. J.A.M.A., 269: 2633, 1993.
18. Voges, G. E., McNeal, J. E., Redwine, E. A., Freiha, F. S. and Stamey, T. S.: Morphologic analysis of surgical margins with positive findings in prostatectomy for adenocarcinoma of the prostate. Cancer, 69: 520, 1992.
19. Walsh, P. C.: Radical prostatectomy for the treatment of localized prostatic carcinoma. Urol. Clin. N. Amer., 7: 583, 1980.
20. Zincke, H., Oesterling, J. E., Blute, M. L., Bergstralh, E. J., Myers, R. P. and Barrett, D. M.: Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J. Urol., part 2, 152: 1850, 1994.
21. Trapasso, J. G., deKernion, J. B., Smith, R. B. and Dorey, F.: The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J. Urol., part 2, 152: 1821, 1994.
22. Ruckle, H. C., Klee, G. G. and Oesterling, J. E.: Prostate-specific antigen: concepts for staging prostate cancer and monitoring response to therapy. Mayo Clin. Proc., 69: 69, 1994.
23. Montie, J. E.: Follow-up after radical prostatectomy or radiation therapy for prostate cancer. Urol. Clin. N. Amer., 21: 673, 1994.
24. Frazier, H. A., Robertson, J. E., Humphrey, P. A. and Paulson, D. F.: Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy? J. Urol., 149: 516, 1993.
25. Catalona, W. J. and Smith, D. S.: 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J. Urol., part 2, 152: 1837, 1994.
26. Paulson, D. F.: Impact of radical prostatectomy in the management of clinically localized disease. J. Urol., part 2, 152: 1826, 1994.
27. Epstein, J. I., Pizov, G. and Walsh, P. C.: Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer, 71: 3582, 1993.
28. Norberg, M., Holmberg, L., Wheeler, T. and Magnusson, A.: Five year follow-up after radical prostatectomy for localized prostate-cancer - a study of the impact of different tumor variables on progression. Scand. J. Urol. Nephrol., 28: 391, 1994.
29. Partin, A. W., Borland, R. N., Epstein, J. I. and Brendler, C. B.: Influence of wide excision of the neurovascular bundle(s) on prognosis in men with clinically localized prostate cancer with established capsular penetration. J. Urol., 150: 142, 1993.
30. Smith, M. R., Biggar, S. and Husaain, M.: Prostate-specific antigen messenger RNA is expressed in non-prostate cells: implications for detection of micrometastases. Cancer Res., 55: 2640, 1995.
31. Folkman, J., Watson, K., Inger, D. and Hanahan, D.: Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature, 339: 58, 1989.
32. Blood, C. H. and Zetter, B. R.: Tumor interactions with the vasculature: angiogenesis and tumor metastasis. Biochim. Biophys. Acta, 1032: 89, 1990.
33. Israeli, R. S., Miller, W. H., Jr., Su, S. L., Powell, C. T., Fair, W. R., Samadi, D. S., Huryk, R. F., DeBlasio, A., Edwards, E. T., Wise, G. J. and Heston, S.: Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays. Cancer Res., 54: 6306, 1994.
34. Catalona, W. J. and Dresner, S. M.: Nerve-sparing radical prostatectomy: extraprostatic tumor extension and preservation of erectile function. J. Urol., 134: 1149, 1985.
35. Rosen, M. A., Goldstone, L., Lapin, S., Wheeler, T. and Scardino, P. T.: Frequency and location of extracapsular extension and positive surgical margins in radical prostatectomy specimens. J. Urol., 148: 331, 1992.
36. Zietman, A. L., Edelstein, R. A., Coen, J. J., Babayan, R. K. and Krane, R. J.: Radical prostatectomy for adenocarcinoma of the prostate: the influence of preoperative and pathologic findings on biochemical disease-free outcome. Urology, 43: 828, 1994.
37. Walsh, P. C., Partin, A. W. and Epstein, J. I.: Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J. Urol., part 2, 152: 1831, 1994.